REDMOND, Wash.--(BUSINESS WIRE)--Oct. 9, 2002--SCOLR, Inc. (OTCBB:SCLL) commented today on the announcement made previously by its global marketing partner, Archer Daniels Midland (NYSE:ADM), that ADM had made its first commercial presentation of Novasoy(R) Daily Dose(TM), the first ADM product in a planned series to include SCOLR's patented CDT(TM) drug delivery technology. The European commercial presentation of Novasoy(R) Daily Dose was made in Paris, France, at the HIE Exhibit in September. SCOLR anticipates the U.S. introduction of Novasoy(R) Daily Dose to corporate partners by ADM this quarter with sales to consumers expected in the first half of 2003.
As previously announced, ADM has licensed SCOLR's patented CDT(TM) drug delivery technology to use exclusively in the development and marketing of dietary supplements for which controlled delivery is essential to providing enhanced product efficacy, safety or simpler, more convenient dosing schedules. ADM will market the products it develops using the CDT(TM) technology on a global basis.
The first ADM product being marketed is Novasoy(R) Daily Dose. This once-a-day supplement provides a consistent, steady delivery of natural-based soy isoflavones (a phytoestrogen) throughout the day. Results of a recent clinical study published in the March 2002 Journal of American College of Obstetricians and Gynecologists concluded that women who took isoflavones three times a day had significant reduction in a variety of menopausal symptoms. In addition, it was determined that isoflavones may help support a healthy cardiovascular system. Novasoy(R) Daily Dose is designed to provide all the benefits of isoflavones in a convenient, single daily dose.
David T. Howard, CEO of SCOLR, commented that, "We are greatly encouraged by the recent news headlines about the benefits of soy isoflavones and what it could mean for the reception of Novasoy(R) Daily Dose.
"The soy isoflavone market is experiencing dramatic growth as a possible alternative to hormone replacement therapy for women. `The Journal of Women's Health' recently cited that 35 million American women -- one third of our female population -- are now perimenopausal and that between 50%-80% of them will experience acute symptoms, such as hot flashes. Up to 50% of women who experience hot flashes will have them for up to five years. Many of these women seek medical and alternative therapy to relieve those symptoms.
"The news has been filled with information about the benefits of consuming a diet rich in soy-based foods. Retail sales of soyfoods in the U.S. alone are growing and expected to surpass $3.5 billion this year, according to a USA Today report on the Women's Health Initiative study.
"It's plainly evident that the benefits of soy isoflavones are substantial, important and growing with each new report. We are pleased and proud to partner SCOLR's patented technology with ADM's expertise in the natural nutraceutical market to develop better performing dietary supplements," Howard said.
Based in Redmond, Washington, SCOLR, Inc. (formerly Nutraceutix, Inc.) is a biopharmaceutical company leveraging specialized knowledge, proprietary and patented products and technologies, such as the patented CDT(TM) Controlled Delivery Technology platform, to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. SCOLR currently operates in two business segments -- drug delivery and nutraceuticals. Its CDT(TM) drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees.
Established partnerships with pharmaceutical, OTC and natural products industry companies enable SCOLR to co-develop new products and to add value and protection to existing product franchises. For more information on SCOLR, please call 1.800.548.3222 or visit http://www.nutraceutix.com/.
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 37A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of the arrangements with the Company's product development partners, the ability of the Company to meet its financial projections, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements whether as a result of new information or otherwise.